Founded in 2001 and headquartered in Cologne, Germany, Axiogenesis is one of a small number of companies specializing in induced pluripotent stem cell (iPSC) products. The company also has an American subsidiary that was founded in 2014 and is located in Philadelphia, Pennsylvania. Since its launch, the company has grown into a market leader for in vitro models of healthy and diseased cell types and tissue. [Read more…]
[Featured on MarketResearch.com] 4 Key Metrics You Need to Know to Invest in the Cord Blood Sector
MarketResearch.com has posted an article titled, “4 Key Metrics You Need to Know to Invest in the Cord Blood Sector,” featuring BioInformant’s analytics for the cord blood banking market.
An excerpt is included below:
“If you are an investor considering an opportunity within the cord blood market, the market can initially appear technical and confusing. However, if you focus on four key metrics, you can quickly and easily assess the technical attributes that matter, including market size, market potential, market competition, and market growth rates.”
A trusted business partner of ours, MarketResearch.com has been selected by Inc. 5000 Magazine as one of America’s fastest growing private companies.
If You’re Investing in the Cord Blood Market, You Need to Know These Metrics [Infographic]
Hematopoietic Stem Cell Transplant Rates, Utilization of Cord Blood, Awareness Rates, and More
The cord blood banking market has emerged gradually over the past 40 years, as 1974 was the first year in which it was proposed that stem and progenitor cells were present in human cord blood. In the forthcoming years it was established that cord blood stem cells had similar properties as bone marrow and could be used as an alternative. Because it is a rich source of highly primitive hematopoietic stem cells, umbilical cord blood has enormous regenerative potential for stem cell based therapy, both for the treatment of hematological and non-hematological disorders.
Business of Commercializing Induced Pluripotent Stem Cells [Infographic]
As a provider of induced pluripotent stem cell (iPSC) products and technologies, you need to make effective product development decisions, generate improved revenues, and take market share from your competition.
To do this, you need to be educated about prevailing market conditions. This involves knowing which stem cell types are showing the most promise and understanding methods through which these cells could be commercialized.
Stem cells are still a relatively new discovery, as the first stem cells were discovered in human cord blood in 1978, the first mouse embryonic stem cells were derived in 1981, and it was not until 2006 that induced pluripotent stem cells (iPSCs) were produced for the first time.
iPSC Market: 3 Major Market Forces (and Why You Should Care) | Infographic
The induced pluripotent stem cell (iPSC) market first emerged in 2006, when iPSC technology was pioneered by Shinya Yamanaka’s lab at Kyoto University in Japan. The shocking discovery that the introduction of four transcription factors into adult cells could convert them into pluripotent stem cells sent waves of excitement throughout the scientific community.
This landmark event came to represent one of the greatest stem cell research discoveries of all time and was memorialized in 2012, when Dr. Yamanaka and Sir John Gurdon were awarded the Nobel Prize “for the discovery that mature cells can be reprogrammed to become pluripotent.”
iPSC technology has since revolutionized how stem cells are derived, differentiated, and acquired in industrial quantities. It has also dramatically affected our understanding of how human cells and organisms develop.